Journal of Pharmacological Sciences, 2018 Treatment with dopaminergic agents result excessive daytime sleepiness (EDS) and some studies have shown the benefit of using modafinil for treating excessive daytime sleepiness of Parkinson's disease (PD) patient.
Rina Ando +9 more
doaj +1 more source
Modafinil Improves Catalepsy in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease; Possible Involvement of Dopaminergic Neurotransmission [PDF]
Advanced Pharmaceutical Bulletin, 2017 Purpose: Modafinil is a vigilance-enhancing drug licensed for narcolepsy. The use of modafinil leads to various neuromodulatory effects with very low abuse potential. A body of evidence suggested that modafinil may have anti-parkinsonian effects.
Reza Vajdi-Hokmabad +4 more
doaj +1 more source
Frontiers in Psychiatry, 2023 IntroductionDespite advances in the treatment of bipolar disorder (BD), most patients do not achieve complete inter-episode recovery and functional disability is common.
Jessica M. Lipschitz +11 more
doaj +1 more source
Comparative potential for generating spontaneous signals for abuse and dependence among drugs used for attention deficit hyperactivity disorder: A disproportionality analysis in VigiBase®. [PDF]
Gen PsychiatrABSTRACT Background The comparative liability for abuse and dependence of drugs used for attention deficit hyperactivity disorder (ADHD) has been poorly explored so far. Aims To evaluate the relative potential of medications used for ADHD for generating spontaneous reports of abuse and dependence in international pharmacovigilance data.
Jouanjus E +4 more
europepmc +2 more sources
PLoS ONE, 2013 BackgroundModafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder and obstructive sleep apnea.
Ping Sheng +7 more
doaj +1 more source
Effects of Modafinil on Behavioral Learning and Hippocampal Synaptic Transmission in Rats [PDF]
International Neurourology Journal, 2015 Purpose: Modafinil is a wake-promoting agent that has been proposed to improve cognitive performance at the preclinical and clinical levels. Since there is insufficient evidence for modafinil to be regarded as a cognitive enhancer, the aim of this study ...
Wen-Wen Yan +7 more
doaj +1 more source
Roles of adrenergic α1 and dopamine D1 and D2 receptors in the mediation of the desynchronization effects of modafinil in a mouse EEG synchronization model. [PDF]
PLoS ONE, 2013 BACKGROUND: Synchronized electroencephalogram (EEG) activity is observed in pathological stages of cognitive impairment and epilepsy. Modafinil, known to increase the release of catecholamines, is a potent wake-promoting agent, and has shown some ...
Chang-Rui Chen +5 more
doaj +1 more source
Frequency of modafinil use and means for both benefits and risks of modafinil.
, 2020 Frequency of modafinil use and means for both benefits and risks of modafinil.
Nicola Rycroft (8407251) +2 more
core +1 more source
Bioethical issues on modafinil [PDF]
, 2016 En este artículo se analiza la mejora de la cognición por el modafinilo, un eugeroico -estimulante beneficioso-, que aumenta los estados de vigilia y que, además, es considerado el primer fármaco que merece la denominación de nootrópico.
García Díaz, Paloma
core +1 more source
High resolution mapping of modafinil induced changes in glutamate level in rat brain. [PDF]
PLoS ONE, 2014 Modafinil is marketed in the United States for the treatment of narcolepsy and daytime somnolence due to shift-work or sleep apnea. Investigations of this drug in the treatment of cocaine and nicotine dependence in addition to disorders of executive ...
Mohammad Haris +9 more
doaj +1 more source